Which is the best lipid-modifying strategy in metabolic syndrome and diabetes: fibrates, statins or both?

Tenenbaum, Alexander; Fisman, Enrique Z.
January 2004
Cardiovascular Diabetology;2004, Vol. 3, p1
Academic Journal
Although less clinical intervention studies have been performed with fibrates than with statins, there are evidences indicating that fibrates may reduce risk of cardiovascular events. The potential clinical benefit of the fenofibrate will be specified by the ongoing Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study, which rationale, methods and aims have been just published. Controlled clinical trials show similar or even greater cardiovascular benefits from statins-based therapy in patient subgroups with diabetes compared with overall study populations. Therefore, statins are the drug of first choice for aggressive lipid lowering actions and reducing risk of coronary artery disease in these patients. However, current therapeutic use of statins as monotherapy is still leaving many patients with mixed atherogenic dyslipidemia at high risk for coronary events. A combination statin/fibrate therapy may be often necessary to control all lipid abnormalities in patients with metabolic syndrome and diabetes adequately, since fibrates provide additional important benefits, particularly on triglyceride and HDL-cholesterol levels. Thus, this combined therapy concentrates on all the components of the mixed dyslipidemia that often occurs in persons with diabetes or metabolic syndrome, and may be expected to reduce cardiovascular morbidity and mortality. Safety concerns about some fibrates such as gemfibrozil may lead to exaggerate precautions regarding fibrate administration and therefore diminish the use of the seagents. However, other fibrates, such as bezafibrate and fenofibrate appear to be safer and better tolerated. We believe that a proper co-administration of statins and fibrates, selected on basis of their safety, could be more effective in achieving a comprehensive lipid control as compared with monotherapy.


Related Articles

  • Cardiovascular Disease Risk Factors in Youth With Type 1 and Type 2 Diabetes: Implications of a Factor Analysis of Clustering. Elizabeth J. Mayer-Davis; Bo Ma; Andrew Lawson; Ralph B. D’Agostino Jr.; Angela D. Liese; Ronny A. Bell; Dana Dabelea; Lawrence Dolan; David J. Pettitt; Beatriz L. Rodriguez; Desmond Williams // Metabolic Syndrome & Related Disorders;Apr2009, Vol. 7 Issue 2, p89 

    Background:The extent to which cardiovascular disease (CVD) risk factors cluster in youth with a diagnosis of type 1 (T1DM) or type 2 diabetes mellitus (T2DM) is unclear. Therefore, we aimed to evaluate potential clustering of traditional CVD risk factors that may reflect an unmeasured but...

  • WHO: Metabolic syndrome not a useful diagnostic tool. Brannon, Matthew // Endocrine Today;Apr2010, Vol. 8 Issue 4, p1 

    The article discusses a report from the World Health Organization (WHO) which concluded that metabolic syndrome is not useful as a tool for diagnosis in the prediction of cardiovascular disease (CVD) or diabetes.

  • Serum Alanine Aminotransferase, Metabolic Syndrome, and Cardiovascular Disease in an Australian Population. Olynyk, John K.; Knuiman, Matthew W.; Divitini, Mark L.; Davis, Timothy M. E.; Beilby, John; Hung, Joseph // American Journal of Gastroenterology;Jul2009, Vol. 104 Issue 7, p1715 

    OBJECTIVES:Elevations of serum alanine aminotransferase (ALT) are common and have been associated with metabolic syndrome (Met S) and cardiovascular risk. The aim of this study was to determine whether elevated ALT concentrations are predictive of Met S or cardiovascular events.METHODS:In...

  • Glycated Hemoglobin, Diabetes, and Cardiovascular Risk in Nondiabetic Adults. Selvin, Elizabeth; Steffes, Michael W.; Hong Zhu; Matsushita, Kunihiro; Wagenknecht, Lynne; Pankow, James; Coresh, Josef; Brancati, Frederick L. // New England Journal of Medicine;3/4/2010, Vol. 362 Issue 9, p800 

    Background: Fasting glucose is the standard measure used to diagnose diabetes in the United States. Recently, glycated hemoglobin was also recommended for this purpose. Methods: We compared the prognostic value of glycated hemoglobin and fasting glucose for identifying adults at risk for...

  • Glycated Hemoglobin "A1c" and Diabetes Complications. Almarzouki, Abdullah Abdalrahman; Tashkandi, Emaad; Farooq, Mian Usman // American Journal of Biomedical Sciences;Apr2012, Vol. 4 Issue 2, p153 

    Objectives: This study aimed to highlight the association of HbA1c with diabetic related complications. Material and Methods: This retrospective study has been conducted in endocrinology department of Alnoor Specialist Hospital, Makkah, Saudi Arabia, from January 2007 to December 2009. Data has...

  • Risk Assessment Using Two Different Diagnostic Tools: Metabolic Syndrome and Cardiovascular Risk Score (SCORE)-Data from a Weight Reduction Intervention Study. Willers, Janina; Hahn, Andreas // Food & Nutrition Sciences;Oct2013, Vol. 4 Issue 10, p1028 

    Objective: Risk score models and the diagnosis of a metabolic syndrome are useful for cardiovascular (CV) risk prediction. The identification of individuals with high CV and metabolic risk is essential to provide appropriate prevention and therapy. The present study aims at clarifying whether...

  • Letter from the SMSNA Publications Chair. Broderick, Gregory A. // Urology Times;May2010 Sexual Health Supplement, p2 

    An introduction to the journal is presented in which the editor discusses the topics discussed at the 15th Annual Fall Meeting of the Sexual Medicine Society of North America (SMSNA) in San Diego, California including one by Doctor Martin Miner on the impact of the metabolic syndrome on erectile...

  • Inflammatory Biomarkers in Asian Indian Women with Metabolic Syndrome. Singhania, Pooja R.; Gupta, Garima; Sen Ray, Kasturi // Food & Nutrition Sciences;Oct2013, Vol. 4 Issue 10, p1021 

    Cardiovascular diseases (CVD) are the leading cause of mortality necessitating its early detection. The emergence of newer subclinical biomarkers in addition to the known cardiometabolic risk factors may play an important role in early detection of CVD risk. In the present study, 74 adult...

  • Association between metabolic syndrome and sexual dysfunction among men with clinically diagnosed diabetes. Amidu, Nafiu; Owiredu, William K. B. A.; Alidu, Huseini; Sarpong, Charity; Gyasi-Sarpong, Christian K.; Quaye, Lawrence // Diabetology & Metabolic Syndrome;2013, Vol. 5 Issue 1, p1 

    Background: The worldwide epidemic of diabetes and obesity has resulted in a rapid upsurge in the prevalence of metabolic syndrome (MetS). MetS makes the individual liable to endothelial dysfunction which can initiate sexual dysfunction (SD). This study assessed the association between MetS and...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics